

WntResearch update on a positive interpretation of results from tox study of Foxy-5

WntResearch AB (publ) announces that the tox studies, from which preliminary results were mentioned in a press release on the 29th of June this year, have now been finally analyzed and reported. The preliminary observations have been confirmed and the studies will as previously announced allow the company to continue its development plans aiming for clinical trials with Foxy-5 for the treatment of cancer patients with metastasis.

CEO Bert Junno comments:

“I’m happy to announce the final conclusion of the tox study and to inform that it fully supports the initial conclusion as announced in June this year. The tox study was successful in that it provided us with valuable data that will be of importance in our continued development.”

For more information contact:

Bert Junno, CEO
WntResearch AB (publ)

Tel: +46-707-772209

E-mail: bert.junno@wntresearch.com

About WntResearch AB

WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies, in areas of unmet need, for the treatment of cancer patients. The company has two major drug development projects, Foxy-5 and Box-5. The lead project Foxy-5 is currently being tested in in-vivo models and is planned to enter phase 1 clinical trials in metastatic cancer in 2012.